Coeptis Therapeutics Holdings Inc COEP

Alternate Symbol(s): COEPW

Healthcare Biotechnology

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute ...

NDAQ:COEP - Post by User

Coeptis Therapeutics Holdings Inc

<< Previous

Bullboard Posts

Next >>

(14)
•••

Post by MasterJediJazz2on Feb 20, 2025 12:17pm

33 Views

Post# 36461514

$COEP announces another milestone in joining $700B global AI

$COEP announces another milestone in joining the $700B+ global AI Market. https://nasdaq.com/press-release/coeptis-announces-launch-coep-venture-group-invest-ai-rpa-and-ai-agent-startups-2025

#OpenAi #COEPVentures #AiNews #Blockchain #Token #Coeptis #Ai

<< Previous

Bullboard Posts

Next >>

Micron is getting out of the consumer business when it is needed the most